Jung-Min Ahn, Do-Yoon Kang, Pil Hyung Lee, Young-Keun Ahn, Won-Jang Kim, Chang-Wook Nam, Jin-Ok Jeong, In-Ho Chae, Hiroki Shiomi, Paul Hsien Li Kao, Joo-Yong Hahn, Sung-Ho Her, Bong-Ki Lee, Tae Hoon Ahn, Kiyuk Chang, Jei Keon Chae, David Smyth, Gregg W Stone, Duk-Woo Park, Seung-Jung Park
BACKGROUND: Acute coronary syndromes are commonly caused by the rupture of vulnerable plaque, which often appear angiographically not severe. Although pharmacologic management is considered standard therapy for stabilizing plaque vulnerability, the potential role of preventive local treatment for vulnerable plaque has not yet been determined. The PREVENT trial was designed to compare preventive percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT) with OMT alone in patients with functionally nonsignificant high-risk vulnerable plaques...
October 2023: American Heart Journal